ArticleBMC cancer2025
α-L-fucosidase isoenzymes (FUCA1/FUCA2) as prognostic markers in gliomas: a comprehensive study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundα-L-fucosidases (AFU) including two isozymes (FUCA1 and FUCA2) are implicated in cancer progression, but their integrated role in glioma pathogenesis remains undefined.
methodsUsing data from TCGA, CGGA, GEO, and Open GWAS, we conducted analyses to determine the significance of FUCA1 and FUCA2 in gliomas, with a particular focus on low-grade gliomas (LGG) given their clinical continuum with glioblastoma (GBM). In vitro and clinical experiments verified FUCA1 and FUCA2's functions.
resultsResults showed gliomas have a genetic link to AFU, with its overexpression and hypomethylation associated with diagnosis and poor prognosis. The high-expression group of FUCA1 and FUCA2 had a higher frequency of IDH wild-type status and lacked 1p/19q codeletion. This group also demonstrated stronger macrophage infiltration and immune gene correlation, indicating a poorer prognosis. The AFURS prognostic model, trained in TCGA-LGG + GBM and validated in CGGA mixed glioma cohorts, effectively predicted patient prognosis, and exploratorily suggested potential associations with immune therapy response. Silencing FUCA1 and FUCA2 reduced glioma cell migration, invasion, proliferation, and viability, promoting apoptosis. Interfering with FUCA2 affected the NF-kB signaling pathway. DISCUSSION: In summary, our study underscores AFU alterations' potential role in glioma progression and their value in diagnosis, treatment, and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.